DNLI earnings: next report 2026-08-10, real EPS beat/miss history, analyst consensus Buy, P/E -8.21. Updated 2026-07-23.
Denali Therapeutics (DNLI) Research Hub
Denali Therapeutics (DNLI) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 21.09 USD (-2.23%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -8.21, market cap 3.72B. This hub links to the full technical, earnings and options research available for DNLI.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 21.09 USD (-2.23%) |
| 52-week range | 21.055 USD – 27.3 USD |
| Trend regime | Range |
| 14-day RSI | 22.1 (Oversold) |
| Trailing P/E | -8.21 |
| Market cap | 3.72B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for DNLI
Covered Call on DNLI: how it works, illustrative setup around the real 21.09 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on DNLI: how it works, illustrative setup around the real 21.09 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on DNLI: how it works, illustrative setup around the real 21.09 USD price, max profit/loss, breakeven and when to use it. Educational.
DNLI technical analysis: range, last 21.09 USD, RSI 22.1, 52w range 21.055 USD–27.3 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is DNLI in?
Denali Therapeutics (DNLI) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is DNLI in an uptrend or downtrend?
As of 2026-09-11, DNLI is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is DNLI's trailing P/E ratio?
DNLI's trailing P/E is -8.21, with a market cap of 3.72B. See the earnings research page for full valuation detail.
When does DNLI next report earnings?
DNLI is next scheduled to report earnings on 2026-08-10, with a consensus EPS estimate of -0.72 USD.